Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

Imatinib Mesylate 5ruxolitinib 4ponatinib 4nilotinib 4Azacitidine 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Denosumab 1Decitabine 1CPI-0610 1BID protein, human 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Diseases × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡